BDBM287603 BDBM393497::BDBM413611::BDBM617007::US9567341, Compound C-179

SMILES FC(F)c1ccc(cc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12

InChI Key InChIKey=ANKBZGWFRHIKFI-UHFFFAOYSA-N

Data  1 KI  13 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 287603   

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 1.00E+7nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 4.90E+3nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 4.90E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 4.90E+3nMAssay Description:CYP P450: Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchase...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 1.40E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 23nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataIC50: 4.90E+3nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataKi:  0.838nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent